Literature DB >> 15082503

Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?

Y Yazici, D Erkan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15082503      PMCID： PMC1754974     

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue.

Authors:  Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2007-07       Impact factor: 19.103

2.  Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.

Authors:  Daniel E Furst; Norman Gaylis; Vance Bray; Ewa Olech; David Yocum; Jeffrey Ritter; Michael Weisman; Daniel J Wallace; John Crues; Dinesh Khanna; Gregory Eckel; Newman Yeilding; Peter Callegari; Sudha Visvanathan; Jeannie Rojas; Ronald Hegedus; Laura George; Khalid Mamun; Keith Gilmer; Orrin Troum
Journal:  Ann Rheum Dis       Date:  2007-04-05       Impact factor: 19.103

3.  Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).

Authors:  Liisa M Virkki; Heikki Valleala; Yuya Takakubo; Jorma Vuotila; Heikki Relas; Riitta Komulainen; Riitta Koivuniemi; Urpo Yli-Kerttula; Markku Mali; Susanna Sihvonen; Maija-Liisa Krogerus; Eero Jukka; Satu Nyrhinen; Yrjö T Konttinen; Dan C Nordström
Journal:  Clin Rheumatol       Date:  2011-06-07       Impact factor: 2.980

4.  Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.

Authors:  Alejandro Balsa; Juan Víctor Tovar Beltrán; Rafael Cáliz Cáliz; Isabel Mateo Bernardo; Rosario García-Vicuña; Manuel Rodríguez-Gómez; Miguel Angel Belmonte Serrano; Carlos Marras; Eduardo Loza Cortina; Eva Pérez-Pampin; Vicente Vila
Journal:  Rheumatol Int       Date:  2015-03-13       Impact factor: 2.631

5.  Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy.

Authors:  Atsushi Kaneko
Journal:  Ther Adv Chronic Dis       Date:  2013-01       Impact factor: 5.091

Review 6.  Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.

Authors:  Joseph R Lutt; Atul Deodhar
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists.

Authors:  Federico Navarro-Sarabia; Dolores Ruiz-Montesinos; Blanca Hernandez; Victoria Navarro-Compán; Sara Marsal; Mireia Barcelo; Eva Perez-Pampín; Juan J Gómez-Reino
Journal:  BMC Musculoskelet Disord       Date:  2009-07-23       Impact factor: 2.362

8.  Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Authors:  A Finckh; A Ciurea; L Brulhart; B Möller; U A Walker; D Courvoisier; D Kyburz; J Dudler; C Gabay
Journal:  Ann Rheum Dis       Date:  2009-05-04       Impact factor: 19.103

Review 9.  Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.

Authors:  Andrea Rubbert-Roth; Axel Finckh
Journal:  Arthritis Res Ther       Date:  2009-04-06       Impact factor: 5.156

10.  DAS steered therapy in clinical practice; cross-sectional results from the METEOR database.

Authors:  Emilia Gvozdenović; Ron Wolterbeek; Désirée van der Heijde; Tom Huizinga; Cornelia Allaart; Robert Landewé
Journal:  BMC Musculoskelet Disord       Date:  2016-01-16       Impact factor: 2.362
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.